Sigma® Life Science launches genetically modified human cell lines for breast cancer research
Publication date: 22 July 2011
Author: kdm communications ltd
Tagged with: Sigma Life Science, Sigma-Aldrich, Supriya Shivakumar
Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq: SIAL), today announced the expansion of its CompoZr® Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knockout and knockin cell lines for drug discovery and research. These modified epithelial cell lines are expected to provide researchers with a characterized and known genetic background for basic research and pathway analysis. They are supplied with isogenic parental cell lines to allow high throughput, cell-based screening for drug discovery, target validation and mechanistic studies. For more information visit www.sigma.com/breastcancercells.
Important breast cancer genes – such as Estrogen Receptor, PTEN and HER2 – have been targeted using Sigma Life Science’s proprietary Zinc Finger Nuclease (ZFN) technology, to create stable and heritable genomic knockouts and to provide new cellular models of cancer. These modified human epithelial cell lines, including MCF10A, among others, offer researchers the complete knockout of disease-relevant target gene expression.
Supriya Shivakumar, Global Marketing Manager at Sigma Life Science, said, “These new knockout breast cancer cell lines, created using Sigma’s ground-breaking CompoZr® ZFN technology, are expected to be ideal for high throughput screens to determine whether patient-relevant genetic alterations affect drug sensitivity or drug resistance. Researchers now have immediate access to high-quality knockout isogenic human cell lines, which should reduce the costs and labor required for basic research and drug discovery, and could accelerate the development of personalized medicine.”
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Fast plasma sample cleanup with new Phree Phospholipid Removal Plates (21 May 2012)
- Two overall winners announced at prestigious national award ceremony in London’s Science Museum (18 May 2012)
- New analysis of risk stratification for TYSABRI® published in New England Journal of Medicine (18 May 2012)
- NUCYNTA® ER (tapentadol) tablets provide pain management for patients with Diabetic Peripheral Neuropathy (DPN) (18 May 2012)
- GSK statement on tender offer to acquire Human Genome Sciences (18 May 2012)
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content